Prof. Hidehiko Hara, MD, PhD, is the Associate Professor at the Division of Cardiovascular Medicine, Toho University Ohashi Medical Center.

Prof. Hara is now performing following interventions focusing on ACHD/SHD such as TAVI, MitraClip, ASD, PFO, PDA, LAAC, PVL closure PTSMA etc. He is the Chairman of NPO Structure Club Japan and the 3 Societies Joint Committee (PFO Council). He is also the Academic Councillor of the Japanese Society of Cardiovascular Stroke.

Dr. Kentaro Hayashida graduated from Keio University School of Medicine of Tokyo in 2000. He was a fellow in Massy, France between 2009-2012. He is currently working as the director of the cardiac catheterization laboratory and the transcatheter heart valve program at Keio University. His main research interest includes transcatheter intervention for structural heart disease and he founded the OCEAN-SHD family in 2013 to organize a multicenter research platform in Japan.

He is also a founder and course director of PCR Tokyo valves, a leading conference in the Asia-Pacific region in the field of transcatheter heart valve therapy. He is serving as the editor-in-chief of the journal of transcatheter valvular therapeutics.

He is a fellow of the European society of cardiology (FESC), the American college of cardiology (FACC), and the Japanese society of cardiology (FJCS). He is also proctoring for TAVI for Edwards Lifesciences, Medtronic, and Abbott.

Prof. Hijazi is an interventional cardiologist who specializes in treating congenital and structural heart disease in both children and adults. He is a pioneer in the non-surgical repair of congenital and structural heart defects.

Prof. Hijazi is very prolific with more than 360 peer reviewed published articles, nine books, over 60 book chapters and hundreds of abstracts. His major area of interest is in the development of techniques and catheters/devices to help treat or cure congenital and structural cardiac disease without open-heart surgery.

Subsequently, he has been a primary investigator and national PI in testing the Amplatzer family of intracardiac devices in the U.S. Prof. These studies resulted in the FDA approving the first ASD closure device and the first VSD device for use in children.

In 2020, Professor Hijazi became the Founding President of a newly formed the PICS Society (Pediatric & Congenital Interventional Cardiovascular Society), the only Society that caters to the needs of pediatric and congenital interventional cardiologists as well as patients with congenital heart disease.

Dr. Gi-Beom Kim is a professor of the department of pediatrics at Seoul National University Children’s Hospital and Seoul National University College of Medicine. He received the M.D. and Ph.D. at Seoul National University. Main clinical interests are catheter intervention for congenital heart disease including percutaneous pulmonary valve implantation, cardiomyopathy, Kawasaki disease, adult congenital heart disease and pulmonary hypertension. Main research interests are technical improvement of trans-catheter intervention for diverse structural heart disease and investigation for pathogenesis of Kawasaki disease through Kawasaki disease epidemiology.

Dr. Sang Yeub Lee is an interventional cardiologist working at Chung-Ang University Gwangmyeong Hospital. His interests in the field are coronary intervention with imaging guidance and distal radial access, structural heart disease intervention especially with intracardiac echocardiographic guidance. 

Alejandro Lemor MD, MS is Assistant Professor and interventional cardiology faculty at University of Mississippi Medical Center. He finished medical school in Peru, did a Masters Degree on Clinical Research, and completed the course Principles and Practice of Clinical Research (PPCR) from Harvard School of Public Health. He completed his Internal Medicine Residency at Icahn School of Medicine at Mount Sinai and his Cardiology and Interventional Cardiology fellowship at Henry Ford Hospital. Authored and coauthored numerous articles, book chapters and abstracts. His research focuses on acute coronary syndrome, high-risk complex PCI, cardiogenic shock, and mechanical circulatory support.

D. Scott Lim, MD is a Professor of Medicine & Pediatrics at the University of Virginia, and has developed a career focusing on novel therapies for heart valve, structural, congenital, and heart failure therapies. He has led as the national primary investigator on transcatheter aortic, mitral, and pulmonary valve trials, as well as worked with many early stage novel cardiac device therapies, particularly in mitral and tricuspid valve disease. In addition to authoring more than 200 scientific publications, 400 presentations, and 50 book chapters, he has been the founding editor through 4 editions of the most popular textbook on congenital heart disease, the Field Guide to Congenital Heart Disease & Repair. He also has spent more than a decade leading a charitable organization to teach cardiac disease and diabetes care to physicians in developing countries.

Dr. Takashi MATSUMOTO is currently a Director of Department of Cardiology and Catheterization Laboratories in Shonan Kamakura General Hospital, Kamakura, Japan. He was a Physician of Cardiovascular Medicine/Interventional Cardiology of Division of Cardiology in Sendai Kousei Hospital, Sendai, Miyagi, Japan from 2014 to 2015. He was also a Chief Physician of Department of Cardiology and Catheterization Laboratories, in Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan from 2021 to 2022.

Dr. Yoshifumi NAKAJIMA is currently Assistant Professor of Division of Cardiology in Department of Internal Medicine, in Iwate Medical University, Morioka, Iwate, Japan. He also was Post-doctoral Scientist, Cedars-Sinai Heart Institute, California, USA, Interventional Cardiology, Structural Heart Disease Program in 2017.
His specialties are Coronary Intervention, Structural Heart Disease Intervention and Sports Medicine.

Dr Pan is a hybrid cardiac physician, holds open heart surgery and percutaneous procedure licenses. He has invented the Percutaneous and Non-fluoroscopical Procedure (PAN procedure), which is a novel percutaneous interventional therapy guided by ultrasound instead of X-ray to win the WHO innovation award in 2022. Currently, there are 11 invented medical instruments authorized by China and Europe to be used in more than 40 countries. Particularly, fully Biodegradable ventricular septal defect occlude device, and Devices for transcatheter mitral valve regurgitation, have gained wide attention. The fully bioabsorbable occluder becomes the milestone of no residual era for structure heart diseases. He has been elected as a foreign expert of top academic associations, such as STS, ACC, ESC.

Dr Promphan is currently Head of Pediatric Heart Center, Queen Sirikit National Institute of Child Health (QSNICH) in Bangkok, Scientific director of Society of Pediatric Cardiology of Thailand (SPCT) and Board Committee of Thai Resuscitation Council (TRC). His major field is Pediatric and Congenital Heart Intervention.

Prof. Shakeel QURESHI is currently Consultant Paediatric Cardiologist of Evelina London Children’s Hospital, Guy’s & St Thomas Hospital Trust. Apart from being a clinical paediatric cardiologist, have developed particular expertise and interest in interventional paediatric cardiology as well as adults with congenital heart disease.   

He has been a visiting professor to many units around the world, where have taught interventional techniques to many doctors and teams.   Also, he was invited to many international scientific conferences around the world and given countless lectures in particular on interventional techniques and the latest developments.   In 2022, He was awarded knighthood in the Queen’s New Year’s Honours list.

Dr. Supaporn ROYMANEE is currently Vice Dean of External relations and special activities, Deputy chief of Naradhiwas Rajanagarindra heart center and Head of Pediatric Cardiology and Congenital Heart Disease Interventionist Division. She was appointed as Clinical Instructor and consultant in 2004 and Assistant professor in 2017.

Her Main research interests are Interventional Congenital and Structural Heart Disease Catheterization, Adult congenital heart disease, Pulmonary Arterial Hypertension and Congenital Heart Disease Surgery.

Dr. Sivakumar SIVALINGAM trained in Malaysia in general surgery, and he obtained postgraduate qualification in General Surgery from the National University of Singapore in 1998. He commenced initial training in cardiothoracic surgery at the National Heart Institute, Kuala Lumpur. Subsequently, he continued training at the West Midland Deanery, United Kingdom as a Specialist Registrar and obtained FRCS(C.Th) from the Royal College of Surgeons, Edinburgh in 2005.

He was appointed as Consultant Cardiothoracic Surgeon at the National Heart Institute, Kuala Lumpur, Malaysia in 2007 and currently hold the position of Clinical Director in Congenital Heart Surgery since 2010. He was promoted as Senior Consultant Cardiothoracic Surgeon on 1st September 2019 then as a Deputy Head of Cardiothoracic & Vascular Surgery Department on 1st January 2020.

He has keen interest in education, surgical training and quality improvement programs in Congenital Heart Surgery.

Prof. Lars SØNDERGAARD is currently a consultant cardiologist of Rigshospitalet, Copenhagen, Denmark and professor of cardiology of University of Copenhagen, Denmark. His special interest in congenital and structural heart diseases, particular interventional procedures. Led the first-in-human transcatheter mitral valve replacement in 2012. Furthermore, first-in-human implantation for the Gore Septal Occluder for device closure of ASD and PFO (WL Gore & Ass.) in 2011, Inter Atrial Septal Device (Corvia) for HFpEF in 2012, Hydra transcatheter aortic valve bioprosthesis (Vascular Innovations) in 2013, Lotus transcatheter aortic valve DepthGuard system (Boston Scientific) in 2016, and Omega (Eclipse Medical) for left atrial appendage closure in 2019.

His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions. Lead principal investigator for several randomized clinical trials including the TEMPO trial (Bosentan in patients with univentricular hearts palliated with Fontan circulation), the NOTION-1 and NOTION-2 trials (investigating the role of transcatheter aortic valve implantation in younger, lower risk patients with aortic stenosis), NOTION-3 randomised trial (coronary re-vascularization before TAVI), the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke), and the GALILEO 4D trial (effect of anti-coagulation versus anti-platelet on subclinical leaflet thrombosis after TAVI).

Dr. Dee Dee Wang is an internationally recognized leader in the field of Structural Heart Imaging and lectures around the world on peri-procedural planning for complex valvular and structural heart disease. She has authored over 150 abstracts and publications in the world's leading medical journals, and co-authored multiple imaging consensus guidance statements for Structural Heart Imaging.

Dr. Wang has been working on peri-procedural planning for transcatheter mitral valve replacement therapies and pioneered the development of a left ventricular outflow tract prediction modeling tool used by health systems around the world to identify patients who may be suitable anatomical candidates for transcatheter mitral valve replacement interventions. She has also developed the pathway for integrating multi-detector CT to optimize patient outcomes in left atrial appendage closure procedures. These initiatives have been proven to increase delivery of personalized patient-centric care, improved patient procedural success rates and minimize procedural complications.

Prof. Jou-Kou WANG is currently Chief of Pediatric Cardiology section and works in National Taiwan University Hospital, Taipei, Taiwan and CEO Taiwan Cardiac Children’s Foundation.

He was appointed as Professor of Pediatrics of National Taiwan University from 2000. He was also appointed as President of Taiwan Society of Pediatric Cardiology from 2012 to 2018.

Janet Fredal Wyman DNP, ACNS-BC, FACC is the Administrative Director for Structural Heart Disease Clinical Services for the Henry Ford Health System; appointed in May 2019 to oversee clinical practice and outcomes as well as programmatic growth of the Structural Heart service line. She is an original member of the multidisciplinary heart team who established the Structural Heart Program in 2010 and has been intimately involved in its growth to a nationally recognized leader in innovative transcatheter therapies, having performed nearly 5000 transcatheter structural heart and multiple first in man procedures. She joined the Heart and Vascular Institute in 2000 as a cardiovascular nurse practitioner.

She has been actively involved with the American College of Cardiology. Having served on numerous committees and councils including Chair of the Cardiovascular Team Leadership Council and Section and Chair of the CV Team Structural Heart Workgroup. She was inducted as a Fellow of the College in March of 2021.

Dr. Jian (James) Ye is a Clinical Professor and the Director of Cardiac Surgery Research at the University of British Columbia. He is also a cardiac surgeon and the Director of Surgical Mitral and Tricuspid Valve Clinic at St. Paul’s Hospital and Vancouver General Hospital. His sub-specialty is complex mitral & tricuspid valve repair, and transcatheter heart valve therapies. Dr. Ye is a pioneer in the development and clinical application of transcatheter heart valve therapies, and has performed over 15 first-in-human transcatheter heart valve procedures for aortic stenosis, failed bioprostheses, pure aortic regurgitation, mitral valve and tricuspid valve regurgitation. He has educated many physicians in TAVI and supervised many transcatheter aortic and mitral valve procedures around the world. He has authored and co-authored over 210 peer-reviewed scientific papers. He has been a reviewer for many high tier journals. Dr. Ye has been invited to give over 200 lecturers at numerous scientific meetings worldwide.

Dr. Yin is Vice Superintendent of the Cheng-Hsin General Hospital and Professor of Medicine at the National Yang Ming Chaio Tung University, Taipei, Taiwan. He is also the Past President of the Taiwan Society of Cardiovascular Interventions.

He is a well-known interventional cardiologist and a frequently invited faculty member of interventional conferences, such as TCT (USA), ESC, EuroPCR, London Valves (Europe), CCT, etc. 

Currently he actively engages in transcatheter heart valve interventions and serves as a proctor of Medtronic, Boston Scientific, Abbott and Edwards TAVR devices. He has more than 850 case experiences on transcatheter heart valve interventions, including TAVR, aortic and mitral valve-in-valve, MitraClip, and repair of paravalvular leakages, by 2022.
Dr. Yin has led the nationwide registries on heart failure with reduced ejection fraction and on treatment of diabetic patients with acute coronary syndrome of the Taiwan Society of Cardiology and has participated in many international clinical trials. He has published widely in the Circulation Cardiovascular Interventions, Circulation Image, JACC Cardiovascular Interventions, Journal of the American Heart Association, International Journal of Cardiology, etc.

Dr Gerald Yong is an interventional cardiologist who has an interest in coronary artery disease, structural/valvular heart disease, coronary angioplasty and stenting, percutaneous closure of cardiac defects, percutaneous closure of prosthetic paravalvular leaks, valvuloplasties and transcatheter aortic valve implantation (TAVI). He also has a special interest in complex coronary interventions including bifurcation stenting and chronic total occlusions.
Dr Yong is a consultant interventional cardiologist at Fiona Stanley Hospital (FSH) and St John of God Hospital Murdoch and in private practice at Wexford Medical Centre. He is the head of structural heart intervention at FSH and the interventional head of the WA High Risk Aortic Stenosis and TAVI programme which is based at FSH. He participates in the on-call roster for general cardiology and acute angioplasty at FSH.